Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 20:14:1034542.
doi: 10.3389/fnagi.2022.1034542. eCollection 2022.

Prevalence and risk factors of sarcopenia without obesity and sarcopenic obesity among Chinese community older people in suburban area of Shanghai: A cross-sectional study

Linqian Lu  1   2   3 , Xiangfeng He  2 , Yanping Song  2 , Min Zhuang  3 , Xie Wu  3 , Nan Chen  1   2   3
Affiliations

Prevalence and risk factors of sarcopenia without obesity and sarcopenic obesity among Chinese community older people in suburban area of Shanghai: A cross-sectional study

Linqian Lu et al. Front Aging Neurosci. .

Abstract

Objectives: The aim of the present study was to explore the prevalence and risk factors of sarcopenia without obesity (S) and sarcopenic obesity (SO) among community-dwelling older people in the Chongming District of Shanghai, China, according to the Asian Working Group for Sarcopenia (AWGS) 2019 Consensus as the diagnostic criteria of sarcopenia.

Methods: In this cross-sectional study, a total of 1,407 subjects aged ≥65 years were included, where the mean age of the subjects was 71.91 ± 5.59 years and their mean body mass index (BMI) was 24.65 ± 3.32 kg/m2. According to the Asian Working Group for Sarcopenia (AWGS) 2019 Consensus, sarcopenia was defined as a low appendicular skeletal muscle mass index (≤7.0 kg/m2 in males and ≤5.7 kg/m2 in females), decreased handgrip strength (<28.0 kg in males and <18.0 kg in females), and/or low gait speed (<1.0 m/s) or poor 5-time chair stand test (5CST) (≥12s). The SO met both the diagnostic criteria for sarcopenia and obesity, meanwhile obesity was defined as an increased percentage of body fat (PBF) (≥25% in males and ≥35% in females). Univariate and multiple logistic regression analyses were performed to explore the risk factors of both S and SO.

Results: The prevalence of S and SO was 9.74% (M: 9.29%, F: 10.05%) and 9.95% (M: 13.94%, F: 7.14%). Lower BMI (OR = 0.136, 95% CI: 0.054-0.340, p < 0.001), lower hip circumference (OR = 0.858, 95% CI: 0.816-0.903, p < 0.001), farming (OR = 1.632, 95% CI: 1.053-2.530, p = 0.028), higher high-density lipoprotein cholesterol (HDL-C) level (OR = 2.235, 95% CI: 1.484-3.367, p < 0.001), and a sleep duration <7 h (OR = 0.561, 95% CI: 0.346-0.909, p = 0.019) were risk factors for S. While aging (70-74 y, OR = 1.923, 95% CI: 1.122-3.295, p = 0.017; 75-79 y, OR = 3.185, 95% CI: 1.816-5.585, p < 0.001; ≥80 y, OR = 7.192, 95% CI: 4.133-12.513, p < 0.001), male (OR = 1.981, 95% CI: 1.351-2.904, p < 0.001), higher BMI (OR = 4.865, 95% CI: 1.089-21.736, p = 0.038), higher monocyte level (OR = 4.203, 95% CI: 1.340-13.181, p = 0.014), and a sleep duration >9 h (OR = 1.881, 95% CI: 1.117-3.166, p = 0.017) were risk factors for SO.

Conclusion: Our study showed the high prevalence of S and SO among community-dwelling older people in the Chongming District. The SO was more prevalent in males. Behavioral factors and lifestyle (such as farming and sleep duration) were associated more with the development of S, while age and male gender were associated more with the development of SO.

Keywords: older people; prevalence; risk factor; sarcopenia; sarcopenic obesity; suburban.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The flowchart of our study.
Figure 2
Figure 2
The prevalence of sarcopenia without obesity (S) and sarcopenic obesity (SO) stratified by gender.
Figure 3
Figure 3
(A) The trend in the prevalence of sarcopenia without obesity (S) and sarcopenic obesity (SO) stratified by age in all subjects. (B) The trend in the prevalence of sarcopenia without obesity (S) and sarcopenic obesity (SO) stratified by age in males. (C) The trend in the prevalence of sarcopenia without obesity (S) and sarcopenic obesity (SO) stratified by age in males.
Figure 4
Figure 4
(A) The prevalence of sarcopenia without obesity (S) and sarcopenic obesity (SO) in low, moderate, and high physical activity (PA) levels in all subjects. (B) The prevalence of sarcopenia without obesity (S) and sarcopenic obesity (SO) in low, moderate, and high physical activity (PA) levels in males. (C) The prevalence of sarcopenia without obesity (S) and sarcopenic obesity (SO) in low, moderate, and high physical activity PA levels in all females.
Figure 5
Figure 5
The risk factors for sarcopenia without obesity (S) according to the univariate and multivariate logistic regression analyses.
Figure 6
Figure 6
The risk factors for sarcopenic obesity (SO) according to the univariate and multivariate logistic regression analyses.
See this image and copyright information in PMC

References

    1. Alexandre T. d. S., Duarte Y. A. d. O., Santos J. L. F., Wong R., Lebrão M. L. (2014). Prevalence and associated factors of sarcopenia among elderly in Brazil: findings from the SABE study. J. Nutr. Health Ag. 18, 284–290. 10.1007/s12603-013-0413-0 - DOI - PubMed
    1. Andrew N. H, Tomas V., Poulami M., Alan C. (2010). HDL lipids and insulin resistance. Current Diabetes Reports 10, 78–86. 10.1007/s11892-009-0085-7 - DOI - PubMed
    1. Batsis J. A., Villareal D. T. (2018). Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Endocrinology 14, 513–537. 10.1038/s41574-018-0062-9 - DOI - PMC - PubMed
    1. Calle E. E., Teras L. R., Thun M. J. (2005). Obesity and mortality. New Engl. J. Med. 353, 2197–2199. 10.1056/NEJM200511173532020 - DOI - PubMed
    1. Cereda E. (2012). Mini nutritional assessment. Curr. Opin. Clin. Nutr. Metab. Care 15, 29–41. 10.1097/MCO.0b013e32834d7647 - DOI - PubMed